Current Hb targets for the correction of anemia mainly are based on clinical trials (ESAs) conducted several years ago or clinical practice guidelines for diagnosis and treatment of renal anemia in China (Ku et al., 2023; Work Group on guidelines for, 2021) or the KDIGO Clinical Practice Guideline for Anemia (KDIGO Anemia Work Group, 2012). This evidence concerns the gene GSTM1 and anemia (phenotype).